...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Cachexia, Sarcopenia and Muscle >The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study
【24h】

The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study

机译：慢性心力衰竭和恶病质患者中富含高热量蛋白质的口服营养补充剂对生活质量，身体成分和炎症指标的影响：一项随机，双盲先导研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The prevalence of cardiac cachexia in chronic heart failure is approximately 5% to 15% and 18-month mortality rates can reach 50%. Treatment with angiotensin-converting enzyme inhibitors and beta-blockers may confer some benefit but no proven therapy exists. We tested the effects of an oral nutritional supplement in cachectic patients with heart failure. This was a prospective, randomized, double-blind, placebo-controlled pilot study which randomized 29 patients to a high-caloric (600?kcal) high-protein (20?g) oral nutritional supplement or placebo for a duration of 6?weeks in addition to the patients’ usual food intake. At baseline, 6?weeks, and 18?weeks, we measured body weight, quality of life, body composition, heart function, laboratory parameters, and exercise performance. Edema-free body weight increased in 19 of 20 patients receiving intervention at 6?weeks and in 17 of 19 patients at 18?weeks with an average weight gain of 2.0?±?1.7?kg (3.1?±?2.4%, p?=?0.0001) and 2.3?±?3.1?kg (3.6?±?4.7%, p?=?0.007) at 6 and 18?weeks, respectively. Most of the weight gain was fat tissue with an absolute gain of 1.5?±?1.7?kg (p?=?0.003) and 1.6?±?2.7?kg (p?=?0.008). A significant improvement in quality of life and decrease in serum levels of tumor necrosis factor-α were observed (p?
机译：在慢性心力衰竭中，心脏恶病质的患病率约为5％至15％，18个月的死亡率可达到50％。用血管紧张素转换酶抑制剂和β-受体阻滞剂治疗可能会带来一些益处，但尚无经过证实的治疗方法。我们测试了口服营养补充剂对患有恶心病的恶病质患者的作用。这是一项前瞻性，随机，双盲，安慰剂对照的先导研究，将29例患者随机分配至高热量（600kkcal）高蛋白（20μg）口服营养补充剂或安慰剂中，持续6周。除了患者通常的食物摄入量。在基线，第6周和第18周时，我们测量了体重，生活质量，身体成分，心脏功能，实验室参数和运动表现。 6周时接受干预的20名患者中有19名无水肿体重增加，而18周时接受干预的19名患者中有17名患者中的17名平均体重增加了2.0？±？1.7？kg（3.1？±？2.4％，p?。在第6周和第18周时分别为（？0.0001）和2.3？±？3.1？kg（3.6？±？4.7％，p？=？0.007）。体重增加最多的是脂肪组织，绝对增重为1.5±±1.7？kg（p≥0.003）和1.6±±2.7？kg（p≥0.008）。观察到生活质量的显着改善和肿瘤坏死因子-α的血清水平降低（两者均p <0.05）。我们从身体大小和身体组成，实验室参数和生活质量方面论证了患有心力衰竭并具有重大临床益处的恶病质患者中口服营养补充剂的可行性（www.clinicaltrials.gov标识符NCT00654719）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号